CIENCIASMEDICASNEWS: 2025

domingo, 7 de diciembre de 2025

American Society of Hematology +++

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time. https://www.news-medical.net/news/20251207/Fixed-duration-therapy-works-as-effectively-as-continuous-treatment-for-chronic-lymphocytic-leukemia.aspx 7 Dec 2025 Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation. https://www.news-medical.net/news/20251207/Chemotherapy-based-conditioning-matches-outcomes-of-total-body-irradiation-for-MRD-negative-B-ALL.aspx 7 Dec 2025 Many families of children with leukemia face significant financial hardship during treatment Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child's treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities. https://www.news-medical.net/news/20251207/Many-families-of-children-with-leukemia-face-significant-financial-hardship-during-treatment.aspx

Pre-workout supplements linked to dangerously short sleep

https://www.news-medical.net/news/20251205/Pre-workout-supplements-linked-to-dangerously-short-sleep.aspx New research shows that young Canadians who take pre-workout supplements are more than twice as likely to sleep five hours or less, raising new questions about how workout stimulants may be affecting recovery, mood, and next-day performance.

Gout for the Holidays Lars J Grimm, MD, MHS |

https://reference.medscape.com/slideshow/gout-knowledge-6005952?ecd=wnl_critimg_251205_mscpref_etid7925510&uac=148436CN&impID=7925510#1 Gout is a common form of inflammatory arthritis historically linked to overindulgence in certain rich foods and alcohol. This crystalline-induced arthropathy not only causes painful flares, but it's also associated with increased all-cause mortality risk.

Most Read Cancer Science & Oncogenesis

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_251205

‘Miracle’ GLP-1 weight loss drugs could complicate some pregnancies Jessica Hamzelou | MIT Technology Review | December 4, 2025

https://geneticliteracyproject.org/2025/12/04/miracle-glp-1-weight-loss-drugs-could-complicate-some-pregnancies/

Groundbreaking blood test for multiple myeloma

https://www.statnews.com/sponsor/2025/12/06/groundbreaking-blood-test-for-multiple-myeloma/

Boehringer Ingelheim prepares schizophrenia app for FDA submission after trial results The app targets symptoms like lack of motivation and inability to experience pleasure

https://www.statnews.com/2025/12/05/boehringer-schizophrenia-app-trial-data-fda-submission/ By Mario AguilarDec. 5, 2025 Health Tech Correspondent

‘Remarkable’ drug results against an aggressive leukemia

https://www.statnews.com/2025/12/06/ash-meeting-syndax-drug-for-acute-myeloid-leukemia/

FDA Approves Voyxact for Primary Immunoglobulin A Nephropathy +...

https://checkrare.com/

Transforming Clinical Outcomes with Early Treatment of Lysosomal Disorders +++

https://checkrare.com/learning/p-transforming-clinical-outcomes-with-early-treatment-of-lysosomal-disorders/ Goker-Alpan, MD, David F. Kronn, MD, Uma Ramaswami, MD, Liz Jalazo, MD, and Lindsay Torrice, MD examine the evidence available to address how to monitor, and possibly treat, children with lysosomal diseases that were diagnosed by newborn screening or soon after birth. PAH Clinical Research Highlights: CHEST 2024 https://checkrare.com/learning/p-pah-clinical-research-highlights-chest-2024/ Jean Elwing, MD provides an overview of the latest clinical research about PAH. Skeletal Involvement in Lysosomal Disorders https://checkrare.com/learning/p-skeletal-involvement-in-lysosomal-disorders/ Ozlem Goker-Alpan, MD and Ravi Kamath, MD, PhD discuss best practices to identify and treat bone problems associated with lysosomal disorders.

Immune Thrombocytopenia Clinical Research Highlights: ISTH 2025 +++

https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/ Shruti Chaturvedi, MD provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP Consider Rare: Suspecting and Diagnosing Hereditary Angioedema https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/ Jonathan A Bernstein, MD discusses hereditary angioedema (HAE) and it's early signs and symptoms, which can lead to faster diagnosis and initiation of effective therapy for the person with HAE. Fabry Disease Research Highlights https://checkrare.com/learning/p-fabry-disease-research-highlights-2025/ Eric Wallace, MD provides a summary of clinically relevant data presented at WORLDSymposium 2025 that can enhance the care of patients with Fabry disease.

Lysosomal Disorders and the Brain +++

https://checkrare.com/learning/p-lysosomal-disorders-and-the-brain/ Ozlem Goker-Alpan, MD and Raphael Schiffmann, MD discuss best practices to identify and treat neurologic problems associated with lysosomal disorders. Case Studies in Diagnosing and Managing FOP https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ Christiaan Scott, MD and Raphaella Stander, MBCHB discuss three case studies to provide physicians with education on best practices to suspect and diagnose FOP. Hemophilia Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/ Steven Pipe, MD provides a summary of data presented at the International Society of Thrombosis and Haemostatis Congress that can enhance the care of patients with hemophilia.

Consider Rare: Suspecting and Diagnosing CIDP +++

https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-cidp/ Jeffrey Allen, MD provides an overview on the diagnostic delays that often occur in patients with CIDP as well as best practices to suspect and diagnose this rare condition more efficiently. Immune Thrombotic Thrombocytopenic Purpura (iTTP) Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/ Shruti Chaturvedi, MD provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. Myasthenia Gravis Clinical Research Highlights: AAN 2025 https://checkrare.com/learning/p-myasthenia-gravis-clinical-research-highlights-aan-2025/ James Howard Jr, MD provides a summary of clinically relevant data presented at AAN 2025 that can enhance the care of patients with myasthenia gravis.kidney disorders.

A Cryptic Case: When You Don’t Know What You Don’t Know Melissa Walton-Shirley, MD December 02, 2025 +++++ ++++ +

Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions Authors: Judith Eelloo, RGN, RSCN, MPhil; Darren Hargrave, MD; Zhichao Wang, MD, MPH; Kaleb Yohay, MD

https://www.medscape.org/viewarticle/optimizing-management-nf1-associated-plexiform-neurofibromas-2025a1000rv5?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251206-OUS-HONC-optimizing-management-nf1-associated-plexiform-neurofibromas-2025a1000rv5-cta

The Hidden Hurdle: Practical Insights on Drug-Drug Interactions in Prostate Cancer Management Authors: Aurelius Omlin, MD; Bertrand Tombal, MD, PhD; Marzia Del Re, PharmD, PhD; Louisa Fleure, RN, MSc

https://www.medscape.org/viewarticle/1003015_sidebar10?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251206-1003015-ES_LANG-HONC

Expanding the Frontiers of HER2-Targeted Therapy in Gynecologic Cancers Authors: Ana Oaknin, MD, PhD; Susana Banerjee, MBBS, MA, FRCP, PhD; Ramez Eskander, MD; Diana N. Ionescu, MD

https://www.medscape.org/viewarticle/expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251206-OUS-HONC-expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv-cta

Immunotherapy in Early-Stage Cancers: Multidisciplinary Team Best Practices Authors: Nadia Harbeck, MD, PhD; Enriqueta Felip, MD; Elizabeth Mittendorf, MD; Suresh Senan, MD

https://www.medscape.org/viewarticle/1002762?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251206-OUS-HONC-1002762-cta

Do you Know These Rare Diseases? +++++++ +

Do you Know These Rare Diseases? Fanconi Anemia https://emedicine.medscape.com/article/960401-overview?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929 Tuberculous Meningitis https://emedicine.medscape.com/article/1166190-overview?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929 Fibrous Dysplasia Pathology https://emedicine.medscape.com/article/1998464-overview?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929 Brown-Sequard Syndrome https://emedicine.medscape.com/article/321652-overview?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929 Huntington Disease https://emedicine.medscape.com/article/1150165-overview?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929 Evans Syndrome https://emedicine.medscape.com/article/955266-overview?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929 Best Disease https://emedicine.medscape.com/article/1227128-overview?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929 Why Use Medscape AI? Find Accurate, Up-to-Date Treatment Guidelines in Seconds https://www.medscape.com/ai-search?ecd=mkm_ret_251207_mscpmrk-OUS_InFocus_etid7922929&uac=148436CN&impID=7922929

Why does CRC stand out from other rising cancers across age groups (Medscape AI) +... +++++ ++ +++

sábado, 6 de diciembre de 2025

Long-awaited results of GLP-1 trial in Alzheimer’s disease show disappointing results Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.+++++

Long-awaited results of GLP-1 trial in Alzheimer’s disease show disappointing results Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease. https://www.drugdiscoverynews.com/long-awaited-results-of-glp-1-trial-in-alzheimer-s-disease-show-disappointing-results-16865 Weekly Rundown: Former FDA chiefs rebuke vaccine official's push for stricter review standards FDA updates, pharma tariff agreements, gene editing deals, and more led the news this week. https://www.drugdiscoverynews.com/weekly-rundown-former-fda-chiefs-rebuke-vaccine-official-s-push-for-stricter-review-standards-16863 Quantum chemistry meets cancer treatment QDX and Prelude Therapeutics are developing drugs that selectively target the JAK2 V617F mutation, offering hope for patients with myeloproliferative neoplasms. https://www.drugdiscoverynews.com/quantum-chemistry-meets-cancer-treatment-16860 How small molecule tau inhibitors could treat Alzheimer’s disease While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease. https://www.drugdiscoverynews.com/how-small-molecule-tau-inhibitors-could-treat-alzheimer-s-disease-16849 A more electric language for biology Bioelectricity is a potent lever for controlling health. What would it look like to treat the body electrically, rather than chemically? https://www.drugdiscoverynews.com/a-more-electric-language-for-biology-16848

Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Authors: Sarah Donahue, MPH, NP, AOCNP; Erika Hamilton, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/1002936?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251205-OUS-HONC-1002936-cta

Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact Authors: Jaume Capdevila, MD, PhD; Gary Bloom; Umberto Malapelle, PhD; Lori J. Wirth, MD

https://www.medscape.org/viewarticle/1002660?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251205-OUS-HONC-1002660-cta

The FDA’s Estrogen Revelation: Time to Prescribe +++

The FDA’s Estrogen Revelation: Time to Prescribe The FDA’s Estrogen Revelation: Time to Prescribe Rachel S. Rubin, MD https://www.medscape.com/viewarticle/fdas-estrogen-revelation-time-prescribe-2025a1000xkt?ecd=wnl_edit_tpal_etid7932801&uac=148436CN&impID=7932801 December 04, 2025 Coffee May Slow Biological Aging in Severe Mental Illness Coffee May Slow Biological Aging in Severe Mental Illness Megan Brooks https://www.medscape.com/viewarticle/coffee-may-slow-biological-aging-severe-mental-illness-2025a1000y2r?ecd=wnl_edit_tpal_etid7932801&uac=148436CN&impID=7932801 December 05, 2025 Doctors Oppose Quebec Law Tying Compensation to Performance Doctors Oppose Quebec Law Tying Compensation to Performance Evra Taylor https://www.medscape.com/viewarticle/doctors-oppose-quebec-law-tying-compensation-performance-2025a1000y2j?ecd=wnl_edit_tpal_etid7932801&uac=148436CN&impID=7932801 Medscape Canada December 05, 2025

Navigating Myelofibrosis and Anemia: Today's Challenges, Tomorrow’s Solutions Authors: John Mascarenhas, MD; Haifa Kathrin Al-Ali, MD; Francesco Passamonti, MD; Nona C. Baker, Dip.CounsMBACP

https://www.medscape.org/viewarticle/1002681?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251206-OUS-HONC-1002681-cta

PROMO SL November 2025

CAREER RESET: FROM STUCK TO STRONG IN 60 DAYS

Career Reset: From Stuck To Strong In 60 Days By Ivanhoe Broadcast News on November 13, 2025 https://www.ivanhoe.com/smart-living/career-reset-from-stuck-to-strong-in-60-days/

FAMILY RESET: TAKE BACK CONTROL OF YOUR DAY

Family Reset: Take Back Control Of Your Day By Ivanhoe Broadcast News on November 14, 2025 https://www.ivanhoe.com/smart-living/family-reset-take-back-control-of-your-day/

FINANCIAL RESET: THE BUDGET CLEANSE

Financial Reset: The Budget Cleanse By Ivanhoe Broadcast News on November 17, 2025 https://www.ivanhoe.com/smart-living/financial-reset-the-budget-cleanse/

Relearning the Art of Swallowing – In-Depth Doctor’s Interview By Ivanhoe Broadcast News on June 20, 2024

https://www.ivanhoe.com/interview/relearning-the-art-of-swallowing-in-depth-doctors-interview/

HO-HO-HOLD ON TO YOUR MONEY! AVOIDING HOLIDAY SCAMS

Ho-Ho-Hold Onto Your Money! Avoiding Holiday Scams By Ivanhoe Broadcast News on December 12, 2025 https://www.ivanhoe.com/?p=36389&preview=1&_ppp=4dfa1beb1b

PSYCHOLOGY OF THE DEAL: SWIPE SMARTER & SPEND LESS

Psychology of the Deal: Swipe Smarter & Spend Less By Ivanhoe Broadcast News on December 11, 2025 https://www.ivanhoe.com/?p=36386&preview=1&_ppp=1e08ac8a27

SHOULD YOUR BABY BE A CARNIVORE?

Should Your Baby Be a Carnivore? By Ivanhoe Broadcast News on December 10, 2025 https://www.ivanhoe.com/?p=36398&preview=1&_ppp=824522f0b8

FROM PAIN TO POSSIBILITY: CURING SICKLE CELL DISEASE

From Pain to Possibility: Curing Sickle Cell Disease By Ivanhoe Broadcast News on December 9, 2025 https://www.ivanhoe.com/?p=36395&preview=1&_ppp=dfc0b1375c

SHEDDING LIGHT ON ALLERGIES

Shedding Light on Allergies By Ivanhoe Broadcast News on December 8, 2025 https://www.ivanhoe.com/?p=36392&preview=1&_ppp=f7b451fd3f

viernes, 5 de diciembre de 2025

Is Dark Skin the Blind Spot of Dermatology? Carolin Hellerich Medscape Europe December 05, 2025

https://www.medscape.com/viewarticle/dark-skin-blind-spot-dermatology-2025a1000y38

Australian HPV Vaccination Marks Cervical Cancer Milestone Bianca Nogrady Medscape Australia December 05, 2025

https://www.medscape.com/viewarticle/australian-hpv-vaccination-marks-cervical-cancer-milestone-2025a1000y4e

Do ICIs Have Long-Term Survival Benefit? Edited by Gargi Mukherjee December 05, 2025

https://www.medscape.com/viewarticle/do-icis-have-long-term-survival-benefit-2025a1000y48

Can MRI With 15-Channel Dental Coil Improve Detection of Bone Invasion in Head and Neck Cancer? Edited by Vineeta Teotia Medscape UK December 05, 2025

https://www.medscape.com/viewarticle/can-mri-15-channel-dental-coil-improve-detection-bone-2025a1000xwh

A single shot of HPV vaccine may be enough to fight cervical cancer, study finds Research could help spur efforts to protect more girls and young women in low-income countries

https://www.statnews.com/2025/12/04/hpv-vaccine-single-shot-cervical-cancer-prevention/

Don’t let hope expire for children with rare diseases

https://www.statnews.com/sponsor/2025/11/17/dont-let-hope-expire-for-children-with-rare-diseases/

Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns Certain Abbott Diabetes Care sensors may provide incorrect low glucose readings

https://www.statnews.com/2025/12/04/abbott-diabetes-care-faulty-glucose-monitors-deaths-injuries/

Accelerating MASH trials: from biopsy to biomarkers The Lancet Gastroenterology & Hepatology +++ +... (Jan 2026 Volume 11Number 1p1-86)

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00192-X/abstract?dgcid=raven_jbs_etoc_feature_langas Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00233-X/abstract?dgcid=raven_jbs_etoc_feature_langas Accelerating MASH trials: from biopsy to biomarkers The Lancet Gastroenterology & Hepatology https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00352-8/fulltext?dgcid=raven_jbs_etoc_email Jan 2026 Volume 11Number 1p1-86 https://www.thelancet.com/journals/langas/issue/vol11no1/PIIS2468-1253(25)X0012-1

Global strategies to reverse the rise of liver cancer

https://www.bigmarker.com/lancet-webinars/lgcw-liver-cancer?utm_bmcr_source=hubspot_email_od_lancethcc25_lgcw&_hsmi=392838832&_hsenc=p2ANqtz-_y-DuuWzJ5_Wpmlu4MljygVsmMzkVSp7b7Ew4c5lWtit9fySkfNJ786w-f3Th2rFQnbVp1fyNt2ABuz0QsDzLPA93Jlw&hsCtaAttrib=195697774984

Ageing in South-East Asia The Lancet Healthy Longevity ++... ++

https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00126-6/fulltext?dgcid=raven_jbs_etoc_email Nov 2025 Volume 6Number 11 https://www.thelancet.com/journals/lanhl/issue/vol6no11/PIIS2666-7568(25)X0012-X Long-term survival after invasive pneumococcal disease: a matched cohort study using electronic health records in England https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00094-7/fulltext?dgcid=raven_jbs_etoc_feature_lanhl Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer’s Prevention Initiative Generation Study 1 https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00097-2/fulltext?dgcid=raven_jbs_etoc_feature_lanhl

How Are Oral SERDs Changing the Management of Advanced HR-Positive Breast Cancer? Authors: Erica L. Mayer, MD, MPH; François-Clément Bidard, MD, PhD

https://www.medscape.org/viewarticle/how-are-oral-serds-changing-management-advanced-hr-positive-2025a1000xkg?page=1

Quickfire Updates on Gastric/GEJ Cancers: Latest Data in Perioperative Immunotherapy Authors: Geoffrey Ku, MD; Elizabeth Smyth, MD

https://www.medscape.org/viewarticle/1002710?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251205-OUS-HONC-1002710-cta

The Lancet Conference Alerts | Have you read our late-breaking content from BTS Winter Meeting 2025? +... ++

SERIES Prematurity-associated Lung Disease Free with registration until Dec 23, 2025 https://www.thelancet.com/series-do/prematurity-associated-lung-disease?dgcid=hubspot_email_conferencealerts_bts25_lanreslungdisease25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-__j6UyB4FeO0Kowq3ckk2SIn7FfaUJvhYo1AflZ37P4WvA2co1LPBQvsYl9BYQZ4NGnukXAFHYM7PnRcXi4XlmMnOxsQ&_hsmi=391782178&utm_content=391782178&utm_source=hs_email ARTICLES Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial Open Access https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00359-5/fulltext?dgcid=hubspot_email_conferencealerts_bts25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8brHAOrgo0TLFYsVC8Ax2ywPyoCJVj5B8O53LPw1c46gzXm2t14B5K0tt7D4gQXKKRw4wimW0uZWFhvR5BI5vjbqKo_Q&_hsmi=391782178&utm_content=391782178&utm_source=hs_email COMMENTS Efficacy of tezepelumab in reducing oral corticosteroid use in severe asthma Free with registration until Dec 6, 2025 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00395-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_bts25&_hsenc=p2ANqtz-9u6H-tPTgZsO1SDXZnNRCyiV1X2okyWdwHjjDflVzkQIqVM_JUKXT8-ef1ENcrLfX2GOK9pM0nx_Gxh0S8tyIrwKMkYQ&_hsmi=391782178&utm_content=391782178&utm_source=hs_email

Sustainable HIV prevention in Africa +...

https://www.thelancet.com/series-do/sustainable-hiv-prevention-africa?dgcid=hubspot_email_conferencealerts_hivprevention25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9NJ6vVFOB9qj_b22-RlHVqI9nxsfrnvtzhCChrnl6_HyqmP-a4MCuoun2BI8uHClZLk8ZFJ2aTJZ_C1qJiidJKXbcqCg&_hsmi=391905161&utm_content=391905161&utm_source=hs_email This new Series, published by The Lancet HIV and The Lancet Global Health, argues that sustainable HIV prevention depends on shifting from fragmented, donor-led programmes to nationally led, integrated health systems. Countries that adopt an integrated health systems approach can better achieve sustainable HIV prevention outcomes and withstand external funding shocks.

Targeted Therapies for NSCLC: Where Are We Today? Authors: Solange Peters, MD, PhD; Benjamin J. Solomon, MBBS, PhD

https://www.medscape.org/viewarticle/1002896?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251204-OUS-HONC-1002896-cta

Precision Imaging in Cardiac MRI: Late Gadolinium-Enhanced Imaging Authors: James Carr, MD

https://www.medscape.org/viewarticle/precision-imaging-cardiac-mri-late-gadolinium-enhanced-2025a1000nh4?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_421597.20_ace_launch

BREYANZI: Proper Name: lisocabtagene maraleucel

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi?utm_medium=email&utm_source=govdelivery FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US https://content.govdelivery.com/accounts/USFDA/bulletins/3fe588e?reqfrom=share The U.S. Food and Drug Administration today approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first Chimeric Antigen Receptor (CAR) T-cell therapy in the U.S. for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of therapy. Breyanzi is a chimeric antigen receptor CAR T-cell therapy that genetically engineers a patient’s own T-cells to target and kill cancer cells. “Today’s approval represents a major advancement in precision medicine, essentially turning the patient’s immune system into a more effective tool to treat MZL,” Vinay Prasad, M.D., M.P.H., Chief Medical and Scientific Officer and Director of the FDA’s Center for Biologics Evaluation and Research. “The FDA continues to optimize its regulatory authority to expand treatment options in the fight against cancer.” Marginal zone lymphoma is a rare slow-growing cancer of the lymphatic system. It presents about 7% of all B-cell non-Hodgkin lymphoma, with approximately 7,460 new cases occurring every year in the U.S. population. Patients with MZL who failed treatment or relapsed following treatment with upfront therapy have decreased survival. “Today’s approval reflects the FDA’s continuing commitment to advance cell therapies to meet the needs of patients with rare cancers,” said Vijay Kumar M.D., Acting Director, Office of Therapeutic Products in the FDA’s Center for Biologics Evaluation and Research. “In granting approval, FDA took into consideration the high and durable response rate following a one-time treatment in patients with MZL, almost half of whom had either progression within two years of diagnosis or had refractory disease.” The safety and effectiveness of Breyanzi were evaluated in an open-label, multicenter, single-arm trial in adults with relapsed or refractory MZL who had received at least two or more lines of systemic therapy or who relapsed after hematopoietic stem cell transplant (HSCT). Study participants underwent leukapheresis, a process to collect a patient’s own immune cells to manufacture Breyanzi. Patients received a single dose of Breyanzi two to seven days following the completion of preparatory chemotherapy to deplete recipient’s lymphocytes, a type of white blood cells. Among the 77 patients who underwent leukapheresis, 66 patients received the study specified single infusion of Breyanzi, of which 95.5% of patients experienced a response to treatment and 62.1% of patients had complete response without signs of marginal zone lymphoma on imaging scans. The responses were durable after a median follow up of 21.6 months. The most common adverse reactions were cytokine release syndrome (CRS), diarrhea, fatigue, musculoskeletal pain, and headache. The full prescribing information for Breyanzi will be available here. The FDA granted Breyanzi Priority Review and Orphan Drug designation for this application. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products?utm_medium=email&utm_source=govdelivery The FDA granted traditional approval of Breyanzi to Juno Therapeutics, Inc. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review?utm_medium=email&utm_source=govdelivery

Highlights From the Annual Oncology Meeting: Clinical Integration of Therapeutic Innovations in Glioma Authors: Matthias Preusser, MD; Manmeet S. Ahluwalia, MD, MBA, FASCO; L. Nicolas Gonzalez Castro, MD, PhD; Jeremy Pivor

https://www.medscape.org/viewarticle/1002677?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251204-OUS-HONC-1002677-cta

Public Meeting: FDA Rare Disease Day 2026 February 23, 2026

https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/public-meeting-fda-rare-disease-day-2026-02232026?utm_medium=email&utm_source=govdelivery FDA will host Rare Disease Day, a virtual public meeting, on Monday, February 23, 2026 in global observance of Rare Disease Week. The theme is: “Moving Forward. Looking Ahead. An Event for Patients.” The goal of this year’s Rare Disease Day is to explore ways to engage and collaborate with patients and their communities to support and accelerate the development of medical products for rare diseases. We want patients to connect with FDA and stay involved with our outreach and engagement programs to ensure the patient voice informs medical product development and regulation throughout FDA. Panels will discuss: Patient Focused FDA Initiatives Patient Engagement Opportunities Addressing Challenges and Opportunities with AI Technology Utilizing Real World Data and Real World Evidence at FDA 

FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma

jueves, 4 de diciembre de 2025

The overdiagnosis debate in mental health misses the point Whether or not the criteria for mental health diagnoses are strict enough, people need help

https://www.statnews.com/2025/12/04/mental-illness-overdiagnosis-debate-treatment/ By Miranda WolpertDec. 4, 2025 Wolpert is director of mental health at Wellcome.

Capricor says its cell therapy improved heart and muscle function in Duchenne patients The dual outcomes in a Phase 3 study will likely bolster the treatment’s regulatory future

https://www.statnews.com/2025/12/03/capricor-cell-therapy-improves-heart-function-duchenne-patients-phase-3-trial/

Paradigm Health, seeking to use AI to enroll clinical trials, partners with Roche The goal is to reach all kinds of patients, including those who don’t have access to research studies

https://www.statnews.com/2025/12/04/paradigm-health-flatiron-artificial-inteligence/ By Matthew HerperDec. 4, 2025 Senior Writer, Medicine, Editorial Director of Events

What to know about the new flu variant, subclade K And why experts still recommend getting your shot this year

https://www.statnews.com/2025/12/04/flu-shot-effectiveness-h3n2-subclade-k-status-report/

AAT Deficiency Often Missed in COPD | Could Respiratory Therapists Do More? ++++++++ +++

What is the optimal "daily steps" goal for patients with early Alzheimer's disease (Medscape AI)

https://www.medscape.com/ai-search?query=What%20is%20the%20optimal%20%22daily%20steps%22%20goal%20for%20patients%20with%20early%20Alzheimer%27s%20disease&ecd=wnl_tp10_daily_251201_MSCPEDIT_etid7917334&uac=148436CN&impID=7917334

Mortality-weighted severe maternal morbidity: a novel approach to assessing maternal health outcomes

https://link.springer.com/article/10.1186/s12884-025-08526-8?utm_medium=email&utm_source=govdelivery The U.S. Department of Health and Human Services (HHS), Office on Women’s Health (OWH) is pleased to announce the release of a new peer-reviewed publication in BMC Pregnancy and Childbirth, “Mortality-Weighted Severe Maternal Morbidity: A Novel Approach to Assessing Maternal Health Outcomes.” This open-access article adds valuable evidence to the growing body of research aimed at improving maternal health outcomes and advancing high-quality care for all pregnant women. The publication presents a mortality-weighted SMM composite index that accounts for indicator-specific severity and additive harm from co-occurring SMM indicators. The improved SMM metric is relevant to clinicians, community partners, and policymakers in both the assessment and intervention of adverse delivery-related events. The HHS OWH encourages you to reach out and share the article with colleagues and networks working in women’s and maternal health.

GUIDELINE ON ADJUVANTS IN VACCINES FOR HUMAN USE

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adjuvants-vaccines-human-use-see-also-explanatory-note_en.pdf

Join us for the NCSACW’s Upcoming Webinar: Substance Use Trends – The Effects on Child Safety and Family Risk Factors Wednesday, December 17, 2−3 p.m. ET

Join us for the NCSACW’s Upcoming Webinar: Substance Use Trends – The Effects on Child Safety and Family Risk Factors Wednesday, December 17, 2−3 p.m. ET Join the National Center on Substance Abuse and Child Welfare’s (NCSACW) for a webinar exploring how substance use trends affect child safety and family risk factors. National experts will share insights from the National Opioid Environmental Scan, discuss the rise of fentanyl and other substances, and offer strategies to improve outcomes for families. Learn how evolving substance use patterns (e.g., fentanyl, stimulants, cannabis) shape child safety and family well-being. https://cffutures.zoom.us/webinar/register/WN_jGPJ59jsSZ29KluWiX8GSg?utm_source=SAMHSA&utm_campaign=0afa3bd6b0-EMAIL_CAMPAIGN_2025_11_21_08_17_COPY_02&utm_medium=email&utm_term=0_-e218918fdf-167840245#/registration This session highlights strategies to reduce stigma and improve parent engagement in services, assess safety and risk factors with families affected by substance use, and strengthen protective capacities in families. It’s designed for professionals across child welfare, substance use treatment, courts, and health care systems. Topics include: How do evolving substance use patterns affect children and families? How does stigma shape access to services and outcomes for families affected by substance use? What are some strategies to assess safety and risk while building protective capacities in families? Meet our presenters: Nancy K. Young, Ph.D., M.S.W, Executive Director of Children and Family Futures Andrea Sivanich, Ph.D., J.D., Deputy Program Director at the Center for Children and Family Futures (CCFF)

Ultra-processed food: from first tastes to lifelong habits The Lancet Child & Adolescent Health ++... ++ (Jan 2026)

https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00345-1/fulltext?dgcid=raven_jbs_etoc_email Jan 2026 Volume 10Number 1p1-70, e1-e3 https://www.thelancet.com/journals/lanchi/issue/vol10no1/PIIS2352-4642(25)X0013-4 Global prevalence of hypertension among children and adolescents aged 19 years or younger: an updated systematic review and meta-analysis https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00281-0/abstract?dgcid=raven_jbs_etoc_feature_lanchi Quantifying the fatal and non-fatal burden of disease associated with child growth failure, 2000–2023: a systematic analysis from the Global Burden of Disease Study 2023 https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00303-7/fulltext?dgcid=raven_jbs_etoc_feature_lanchi

FDA Pulls Requirement for Asbestos Testing in Talc-Containing Cosmetics Alicia Ault December 04, 2025

https://www.medscape.com/viewarticle/fda-pulls-requirement-asbestos-testing-talc-containing-2025a1000xyv

A Trend That’s Far From Harmless: Toad-Licking Thomas Kron, MD Medscape Europe December 04, 2025

https://www.medscape.com/viewarticle/trend-s-far-harmless-toad-licking-2025a1000xxz

A day in the life: Vicky, Mum to Tiger-Lily 3 December 2025

https://rarerevolutionmagazine.com/a-day-in-the-life-vicky-mum-to-tiger-lily/ Life as a RARE parent can be a mix of worry, uncertainty and fear, but also of great joy, meaning and love. Vicky gives us an insight into parenting Tiger-Lily—the challenges, the importance of having a care circle and most importantly, of living a life of joy My alarm goes off at 6.50am, every single morning. That’s the handover point—when the night carer finishes and my day begins with Tiger-Lily. Life with congenital central hypoventilation syndrome (CCHS) doesn’t come with a pause button. CCHS is a rare neurological condition where the body forgets to breathe automatically, especially during sleep. For Tiger-Lily, it means relying on a ventilator at night, having a tracheostomy, and always needing careful monitoring. But it also means she’s grown up with incredible resilience, and I’ve grown right alongside her. There are thought to be only about 200 children in the UK with CCHS, and around 5,000 worldwide—although we still think this is an underestimate where cases are non-diagnosed. It’s so rare that most doctors and nurses we meet haven’t come across it before. Parenting a child with CCHS makes you a nurse, an advocate, a cheerleader and a project manager all rolled into one. Mornings: waking with alarms Even when brushing my teeth, I’m listening out for the ventilator alarm. It often goes off when Tiger-Lily stirs, and even if it’s nothing serious, my heart still skips. But she’s amazing at managing things herself now—she’ll wake up, take off her oxygen probe and ventilator, and pop on her Swedish nose (a little filter for her trach). After that, mornings look much like anyone else’s: loo, teeth, clothes, breakfast. The difference is the extra checklist—spare Swedish noses, suction machine, saline, catheters, charger. It’s second nature now, but still a juggling act. The school run: book bags and beyond Getting out of the house is always an operation—school bag plus wheely box, suction machine and all the backups. At school she’s greeted by her one-to-one carer and I head to work with my phone on loud, just in case. Sometimes the phone does ring and my stomach drops. Once she fainted at school due to dehydration. For another child it would’ve been a sick day; for Tiger-Lily, it was an emergency. But those moments are rare. Most days she’s just like her classmates—running into school, seeing friends and learning new things. Afternoons and evenings After school, Tiger-Lily might go to a club—she loves dancing and recently shone in a Wizard of Oz show. Seeing her beam on stage made me so proud. On quieter days we’ll head to the park or snuggle up for reading. Evenings have their rhythm: dinner, bath (extra careful around her trach), then bed. She’s usually asleep by 8pm, with her oxygen monitor on. At 9pm her carer arrives for the night shift, and I can exhale, knowing she’s safe and watched over until morning. The circle of care We’re surrounded by people I trust—from carers to school staff. That consistency means I can let Tiger-Lily step out into the world with confidence. Trust is everything, and I’ve learnt that having the right people around us makes the biggest difference. How it’s changed me Tiger-Lily has transformed me. I used to be laid-back; now I’m determined and focused. I’ve even become a runner—something I’d never imagined and I’ve now run two 10ks. Running helps me process everything, and it shows both of us that we can keep moving forward, no matter what. Keep me breathing One huge source of hope has been Keep Me Breathing, the children’s charity based in Hove. They’re pioneering new technology for kids with CCHS, including the VENTO—a wearable CO₂ monitor that’s 90% lighter and 20 times smaller than the bulky equipment we currently use—and, in the longer term, an advanced breathing pacemaker. The thought of something portable that could alert me if her breathing dips and then automatically help her to breathe will be life-changing. It would mean less constant fear, more freedom, and even the possibility of things like swimming or travelling abroad once her tracheostomy can be reversed. Just as importantly, Keep Me Breathing brings families together. When you’re living with something so rare, connecting with people who get it is invaluable. That sense of community has carried me through. Our normal Tiger-Lily is seven now and thriving. She’s independent, clever and at that age where hugs at the school gate are so uncool. I secretly love that, because it means she’s just like any other child her age. Yes, the medical side is always there—alarms, equipment checks, planning. But our life is full of joy too: school runs, homework, bedtime stories, dance shows, days in the park. This is our normal. Busy, sometimes scary, but overflowing with pride and love. And Tiger-Lily amazes me every single day.

FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic?utm_medium=email&utm_source=govdelivery

Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions Authors: Judith Eelloo, RGN, RSCN, MPhil; Darren Hargrave, MD; Zhichao Wang, MD, MPH; Kaleb Yohay, MD

https://www.medscape.org/viewarticle/optimizing-management-nf1-associated-plexiform-neurofibromas-2025a1000rv5?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251203-12077439-ES_LANG-NEUR#expert-commentary-es

Expanding the Frontiers of HER2-Targeted Therapy in Gynecologic Cancers Authors: Ana Oaknin, MD, PhD; Susana Banerjee, MBBS, MA, FRCP, PhD; Ramez Eskander, MD; Diana N. Ionescu, MD

https://www.medscape.org/viewarticle/expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251203-OUS-HONC-expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv-cta

ASH 2025 Preview: Myeloma Abstracts to Watch For +++

News & Perspectives: ASH 2025 Preview: Myeloma Abstracts to Watch For ASH 2025 Preview: Myeloma Abstracts to Watch For Manni Mohyuddin, MD https://www.medscape.com/viewarticle/ash-2025-preview-myeloma-abstracts-watch-2025a1000wt2?ecd=wnl_edit_tpal_etid7924649&uac=148436CN&impID=7924649 Man in Seventies With Blink-Induced Visual Tilt From Stroke Man in Seventies With Blink-Induced Visual Tilt From Stroke Wolfgang Paik https://www.medscape.com/viewarticle/man-seventies-blink-induced-visual-tilt-stroke-2025a1000xrc?ecd=wnl_edit_tpal_etid7924649&uac=148436CN&impID=7924649 Medscape UK December 03, 2025 Trump GLP-1 Deal ‘Move in Right Direction’ Trump GLP-1 Deal ‘Move in Right Direction’ Caroline Messer, MD https://www.medscape.com/viewarticle/trump-glp-1-deal-move-right-direction-2025a1000wt0?ecd=wnl_edit_tpal_etid7924649&uac=148436CN&impID=7924649 December 02, 2025

Highlights from the Annual Neurosurgical Conference: New Standards in Diffuse Lower-Grade Glioma Authors: Mitchel S. Berger, MD; Macarena de la Fuente, MD; Michael Lim, MD

https://www.medscape.org/viewarticle/1002598?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251203-OUS-HONC-1002598-cta

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: What to Expect From New Treatments Authors: Jeffrey A. Allen, MD; Thomas Harbo, MD, PhD

https://www.medscape.org/viewarticle/1002649_sidebar9?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251204-ES_LANG-NEUR-1002649-cta

Frontline Frontiers: Revolutionizing Extensive-Stage SCLC Care Through Treatment Innovation Authors: Solange Peters, MD, PhD; Martin Reck, MD; Melissa Johnson, MD

https://www.medscape.org/viewarticle/1002626?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251204-OUS-HONC-1002626-cta

miércoles, 3 de diciembre de 2025

Microbial warning signs that predict death risk in severe pneumonia

https://www.news-medical.net/news/20251203/Microbial-warning-signs-that-predict-death-risk-in-severe-pneumonia.aspx Researchers uncover a microbial signature in the lungs of severe pneumonia patients. Could this help explain survival differences and hint at new paths for earlier, more accurate prognosis?

Air pollution weakens the life-extending benefits of exercise

https://www.news-medical.net/news/20251203/Air-pollution-weakens-the-life-extending-benefits-of-exercise.aspx A large multi-country study identifies the air pollution levels at which the health benefits of regular physical activity start to decline, offering clearer guidance for staying active in areas with rising PM2.5 exposure.

MPs Warn Mental Health Pilot Faces Funding Risk Dr Rob Hicks

https://www.medscape.com/viewarticle/mps-warn-mental-health-pilot-faces-funding-risk-2025a1000xur

SABCS 2025: Previewing New Data in HR+/HER2- Breast Cancer Avan Armaghani, MD December 02, 2025

https://www.medscape.com/viewarticle/mdangle-sabcs-2025-hr-positive-breast-cancer-preview-2025a100086j

Conference MDAngle: SABCS 2025 HR+/HER2- Breast Cancer December 02, 2025

https://www.medscape.com/viewarticle/mdangle-sabcs-2025-hr-positive-breast-cancer-overview-poll-2025a100086o

FDA OKs Blood-Based Test to Help Diagnose Prostate Cancer M. Alexander Otto, PA, MMSc December 03, 2025

https://www.medscape.com/viewarticle/fda-oks-blood-based-test-help-diagnose-prostate-cancer-2025a1000xv1

Beyond the Tumor: A Comprehensive Approach to Adult Neurofibromatosis 1–Associated Plexiform Neurofibromas Authors: Kaleb Yohay, MD; Mina Lobbous, MD, MSPH; Tobias Walbert, MD, PhD, MPH

https://www.medscape.org/viewarticle/1003125

Editorial p1265 Lenacapavir—time to change the game for everyone The Lancet Infectious Diseases +++ +...

Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in women aged 18–25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00284-1/fulltext?dgcid=hubspot_update_feature_updatealerts_laninf&utm_campaign=update-laninf&utm_medium=email&_hsenc=p2ANqtz--L_JGaXKO7ug0oIeUX3ULppCoCTcUTGP1Tr_FT-L2j7c1BtesnbmSWzZF9awNInGpB2H9dcMtife1hXQb20AJGrltheg&_hsmi=392624890&utm_content=392596276&utm_source=hs_email Estimating measles susceptibility and transmission patterns in Italy: an epidemiological assessment https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00293-2/abstract?utm_campaign=update-laninf&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laninf&_hsenc=p2ANqtz--n4sI29JZqk_zX2t2pU_23ggeyb_PDKrClL0-NlbBaNORHjsJF9hYInckV6I0r6-_N6lYjp4eyfTofAAbpjlR5g0Av8w&_hsmi=392624890&utm_content=392596276&utm_source=hs_email The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research? https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00305-6/abstract?utm_campaign=update-laninf&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laninf&_hsenc=p2ANqtz-__pg6tk7RuxK_aQ-hdrK6QDwq-QGlqXlDT2Bst8Mby_wGy5lLrvj74SsCX9Cj_OxMoh80-dJB9JsWutLwgIrk7K9wdcQ&_hsmi=392624890&utm_content=392596276&utm_source=hs_email Editorial p1265 Lenacapavir—time to change the game for everyone The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/issue/vol25no12/PIIS1473-3099(25)X0012-8

Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Breast Cancer Authors: Stephen R. D. Johnston, MA, FRCP, PhD; Priya Rastogi, MD

https://www.medscape.org/viewarticle/1002908?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251202-OUS-HONC-1002908-cta

Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: The Adjuvant Clinical Trial Populations Explained Authors: Erika Hamilton, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/1002403_sidebar12?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

Breast Cancer Care in 2025: Breakthroughs and Takeaways From Chicago Authors: Massimo Cristofanilli, MD, FACP; Giuseppe Curigliano, MD, PhD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

https://www.medscape.org/viewarticle/1002644_sidebar11?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

Collaborative Care: Navigating Multidisciplinary Management of CLL and MCL for Optimal Patient Outcomes Authors: Jennifer A. Woyach, MD; Peter Dreger, MD; Sanam Loghavi, MD; Josie Montegaard, MSN, AGNP-BC

https://www.medscape.org/viewarticle/1002602_sidebar10?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

Under the Skin: Revolutionizing Immunotherapy Delivery in Lung Cancer Authors: Sanjay Popat, PhD, FRCP; Alba Silverio Pons, RN; Alba Manzaneque, BCOP; Debra Montague

https://www.medscape.org/viewarticle/1002630_sidebar9?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

Navigating Myelofibrosis and Anemia: Today's Challenges, Tomorrow’s Solutions Authors: John Mascarenhas, MD; Haifa Kathrin Al-Ali, MD; Francesco Passamonti, MD; Nona C. Baker, Dip.CounsMBACP

https://www.medscape.org/viewarticle/1002681_sidebar8?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

Personalized Pathways: Tailoring Care for Patients With Newly Diagnosed Multiple Myeloma Authors: Philippe Moreau, MD; Paula Rodriguez Otero, MD, PhD; Roman Hájek, MD, PhD; Evangelos Terpos, MD, PhD; Barbara Leonardi

https://www.medscape.org/viewarticle/1002741_sidebar10?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

Illuminating the Path: New Insights in EGFR-Mutated Advanced NSCLC Authors: Antonio Passaro, MD, PhD; Enriqueta Felip, MD

https://www.medscape.org/viewarticle/1002869_sidebar10?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

argeted Therapies for NSCLC: Where Are We Today? Authors: Solange Peters, MD, PhD; Benjamin J. Solomon, MBBS, PhD

https://www.medscape.org/viewarticle/1002896_sidebar10?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers Authors: Elizabeth Smyth, MD; Samuel J. Klempner, MD, FASCO, Eric Van Cutsem, MD, PhD

https://www.medscape.org/viewarticle/1002919_sidebar3?sso=true&uac=148436CN&ecd=mkm_ret_251201_mscpmrk-ES_CME_etid7907891&impID=7907891

The Clock Is Ticking: Optimizing Ongoing Seizure Response Authors: Lawrence J. Hirsch, MD; Manuel Toledo, MD, PhD; Reetta Kälviäinen, MD, PhD

https://www.medscape.org/viewarticle/1002941_sidebar9?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251202-1002941_ES_NEUR

Hormone Receptor-Positive Metastatic Breast Cancer: Novel Endocrine-Based Strategies and Options After Progression Authors: Volkmar Müller, MD; Erica L. Mayer, MD, MPH

https://www.medscape.org/viewarticle/1002835?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251202-OUS-HONC-1002835-cta

martes, 2 de diciembre de 2025

Rod Kissmee claims ‘‘I have very strong sperm!’: Welcome to the wild west world of social media sperm selling Robyn Vinter | Guardian | December 2, 2025

https://geneticliteracyproject.org/2025/12/02/rod-kissmee-claims-i-have-very-strong-sperm-welcome-to-the-wild-west-world-of-social-media-sperm-selling/

Viewpoint: Environmental toxin hysteria—MIT’s Undark embarrasses with hysteria-driven story aligning itself with false claims that ‘environmental toxins’ (whatever that means) are crippling our health Geoffrey Kabat | December 2, 2025

https://geneticliteracyproject.org/2025/12/02/viewpoint-environmental-toxin-hysteria-mits-undark-embarrasses-with-hysteria-driven-story-aligning-itself-with-false-claims-that-environmental-toxins-whatever-that/

Viewpoint: TB served in a glass—The legislative rush to legitimize raw milk Barbara Pfeffer Billauer | December 2, 2025

https://geneticliteracyproject.org/2025/12/02/viewpoint-tb-served-in-a-glass-the-legislative-rush-to-legitimize-raw-milk/?mc_cid=386ff3e925&mc_eid=b73600b7ac

Targeted Therapies for NSCLC: Where Are We Today? Authors: Solange Peters, MD, PhD; Benjamin J. Solomon, MBBS, PhD

https://www.medscape.org/viewarticle/1002896?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251201-OUS-HONC-1002896-cta

How data science will transform cancer care & research

https://www.statnews.com/sponsor/2025/11/03/how-data-science-will-transform-cancer-care-research/

Racial bias in medicine can be as simple as dismissing Black patients as a ‘hard stick’ Even seemingly small bias-driven assumptions erode trust in health care

https://www.statnews.com/2025/12/02/hard-stick-black-patients-medicine-bias-race/

Expert review finds delaying the hepatitis B vaccine birth dose would increase chronic infections in kids The researchers found a delay would not improve the vaccine’s safety or effectiveness

https://www.statnews.com/2025/12/02/cdc-acip-meeting-hepatitis-b-shots-vaccine-integrity-project/

Marion Nestle still believes that ‘calories count’ A Q&A with the leading nutritionist and author of the new book ‘What to Eat Now’

https://www.statnews.com/2025/12/02/marion-nestle-interview-author-what-to-eat-now/

Pediatric Hemophilia A: Early Factor VIII Use and Lifelong Treatment Planning Authors: Jonathan M. Ducore, MD, MPH; Mindy L. Simpson, MD; Anne M. Gonzales, PT, DPT; Kim L. Schafer, MSN, FNP-C

https://www.medscape.org/viewarticle/pediatric-hemophilia-early-factor-viii-use-and-lifelong-2025a1000wiu?page=1

Patients Progressing on an AI ± CDK4/6 Inhibitors: From Biomarkers to Treatment Strategies Authors: Manali Bhave, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/patients-progressing-ai-cdk4-6-inhibitors-biomarkers-2025a1000wtp?page=1

Istanbul Tragedy: The Poison That Mimics Food Poisoning Michael van den Heuvel

https://www.medscape.com/viewarticle/istanbul-tragedy-poison-mimics-food-poisoning-2025a1000xms

ASH 2025 Preview: Myeloma Abstracts to Watch For Manni Mohyuddin, MD December 02, 2025

https://www.medscape.com/viewarticle/ash-2025-preview-myeloma-abstracts-watch-2025a1000wt2

Do Long-Term PPIs Raise Gastric Tumor Risk? A Study Says Yes Nathalie Raffier Medscape Europe December 02, 2025

https://www.medscape.com/viewarticle/do-long-term-ppis-raise-gastric-tumor-risk-study-says-yes-2025a1000xld

Metformin Plus GLP-1 RAs Tied to Lower Cancer Risk, Mortality Than DPP-4 in T2D Edited by Javed Choudhury December 02, 2025

https://www.medscape.com/viewarticle/metformin-plus-glp-1-ras-tied-lower-cancer-risk-mortality-2025a1000xlb

Quickfire Updates on Gastric/GEJ Cancers: Latest Data in Perioperative Immunotherapy Authors: Geoffrey Ku, MD; Elizabeth Smyth, MD Faculty

https://www.medscape.org/viewarticle/1002710?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251202-OUS-HONC-1002710-cta

Early-life nutrition

https://www.nih.gov/news-events/nih-research-matters/early-life-nutrition

Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact Authors: Jaume Capdevila, MD, PhD; Gary Bloom; Umberto Malapelle, PhD; Lori J. Wirth, MD

https://www.medscape.org/viewarticle/1002660?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251201-OUS-HONC-1002660-cta

Tendon Trouble | Gastroparesis | DASH for Diabetes | Pink Eye | Developmental Language Disorder

https://newsinhealth.nih.gov/2025/12

Study clarifies breast cancer risks linked to genes and family history

https://www.niehs.nih.gov/news/factor/2025/12

Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach Authors: François-Clément Bidard, MD, PhD; Nicola Fusco, MD, PhD

https://www.medscape.org/viewarticle/1002782?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251201-OUS-HONC-1002782-cta

lunes, 1 de diciembre de 2025

Could statins protect against complications after retinal detachment surgery (Medscape AI)

https://www.medscape.com/ai-search?query=Could%20statins%20protect%20against%20complications%20after%20retinal%20detachment%20surgery&ecd=mkm_ret_251126_mscpmrk_ophth_top-content_etid7905904&uac=148436CN&impID=7905904

Why the UK Advised Against Routine Prostate Screening Dr Sheena Meredith Medscape UK December 01, 2025

https://www.medscape.com/viewarticle/why-uk-advised-against-routine-prostate-screening-2025a1000xf6

Are Sexual Side Effects Emerging With GLP-1 Agonists? Mónica M. Bernardo +++++ ++ +

Automated production of lung organoids could revolutionize the development of treatments

https://www.news-medical.net/news/20251201/Automated-production-of-lung-organoids-could-revolutionize-the-development-of-treatments.aspx

Study finds surprising differences in knee injuries between men and women

https://www.news-medical.net/news/20251201/Study-finds-surprising-differences-in-knee-injuries-between-men-and-women.aspx

Updated Canadian guideline aims to raise awareness of new HIV prevention strategies

https://www.news-medical.net/news/20251201/Updated-Canadian-guideline-aims-to-raise-awareness-of-new-HIV-prevention-strategies.aspx

Why potatoes and grains can’t replace each other in a healthy diet

https://www.news-medical.net/news/20251201/Why-potatoes-and-grains-cane28099t-replace-each-other-in-a-healthy-diet.aspx Researchers have shown that white potatoes provide crucial nutrients that Americans lack, yet swapping them for grains triggers significant losses in iron, folate, and other essential nutrients, reshaping our understanding of “healthy carbs.”

Quitting Smoking and Lung Cancer Screening Saves Lives but Could Save Many More Manuela Callari December 01, 2025

https://www.medscape.com/viewarticle/quitting-smoking-and-lung-cancer-screening-saves-lives-could-2025a1000xh4

1 in 10 Young Patients With Cancer Have Metastatic Recurrence Edited by Gargi Mukherjee December 01, 2025

https://www.medscape.com/viewarticle/1-10-young-patients-cancer-have-metastatic-recurrence-2025a1000xgx

PAXG vs Modified FOLFIRINOX for Resectable Pancreatic Cancer: Which Works Better? Edited by Vineeta Teotia Medscape UK December 01, 2025

https://www.medscape.com/viewarticle/paxg-vs-modified-folfirinox-resectable-pancreatic-cancer-2025a1000x9c

Beyond the Buzz: Tumor Treating Fields for Cancer M. Alexander Otto, PA, MMSc December 01, 2025

https://www.medscape.com/viewarticle/beyond-buzz-tumor-treating-fields-cancer-2025a1000xh0

Postpartum Headache Shows Rare Pituitary Apoplexy in Woman Wolfgang Paik Medscape UK December 01, 2025

https://www.medscape.com/viewarticle/postpartum-headache-shows-rare-pituitary-apoplexy-woman-2025a1000xhc

American Heart Association (AHA) Scientific Sessions 2025

https://www.medscape.com/viewcollection/37915?ecd=WNL_conf_cardio_AHA-SPON_251129_MSCPEDIT_etid7905647&uac=148436CN&impID=7905647

Hidden Epidemic: MASLD in Obesity | CRC Risk From Running? ++++++ +++

Rare Clinical Spotlight Exploring Castleman Disease, Cold Agglutinin Disease, and Acute Intermittent Porphyria CME/CNE/CPE Hyatt Regency Orlando Friday, December 5, 2025 | 11:30 AM - 1:00 PM ET

https://na.eventscloud.com/website/87038/ Join us for a truly unique 90-minute deep dive into three rare but clinically significant conditions, Castleman disease (CD), cold agglutinin disease (CAD), and acute intermittent porphyria (AIP), led by six expert faculty who specialize in diagnosing and treating these complex disorders.